<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>995</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15767433</PubmedId>
            <Abstract>The extent to which CD8+ T cells specific for other antigens expand to compensate for the mutational loss of the prominent DbNP366 and DbPA224 epitopes has been investigated using H1N1 and H3N2 influenza A viruses modified by reverse genetics. Significantly increased numbers of CD8+ KbPB1(703)+, CD8+ KbNS2(114)+, and CD8+ DbPB1-F2(62)+ T cells were found in the spleen and in the inflammatory population recovered by bronchoalveolar lavage from mice that were first given the -NP-PA H1N1 virus intraperitoneally and then challenged intranasally with the homologous H3N2 virus. The effect was less consistent when this prime-boost protocol was reversed. Also, though the quality of the response measured by cytokine staining showed some evidence of modification when these minor CD8+-T-cell populations were forced to play a more prominent part, the effects were relatively small and no consistent pattern emerged. The magnitude of the enhanced clonal expansion following secondary challenge suggested that the prime-boost with the -NP-PA viruses gave a response overall that was little different in magnitude from that following comparable exposure to the unmanipulated viruses. This was indeed shown to be the case when the total response was measured by ELISPOT analysis with virus-infected cells as stimulators. More surprisingly, the same effect was seen following primary challenge, though individual analysis of the CD8+ KbPB1(703)+, CD8+ KbNS2(114)+, and CD8+ DbPB1-F2(62)+ sets gave no indication of compensatory expansion. A possible explanation is that novel, as yet undetected epitopes emerge following primary exposure to the -NP-PA deletion viruses. These findings have implications for both natural infections and vaccines.</Abstract>
            <ArticleYear>2005</ArticleYear>
            <ArticlePages>4329-39</ArticlePages>
            <ArticleTitle>Consequences of immunodominant epitope deletion for minor influenza virus-specific CD8+-T-cell responses.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Andreansky</LastName>
                    <ForeName>Samita S</ForeName>
                </Author>
                <Author>
                    <LastName>Stambas</LastName>
                    <ForeName>John</ForeName>
                </Author>
                <Author>
                    <LastName>Thomas</LastName>
                    <ForeName>Paul G</ForeName>
                </Author>
                <Author>
                    <LastName>Xie</LastName>
                    <ForeName>Weidong</ForeName>
                </Author>
                <Author>
                    <LastName>Webby</LastName>
                    <ForeName>Richard J</ForeName>
                </Author>
                <Author>
                    <LastName>Doherty</LastName>
                    <ForeName>Peter C</ForeName>
                </Author>
            </Authors>
            <Affiliations>Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.</Affiliations>
            <ArticleChemicalList>Antigens, Viral;Epitopes, T-Lymphocyte</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; Antigens, Viral(immunology); Bronchoalveolar Lavage Fluid(immunology); CD8-Positive T-Lymphocytes(immunology); Cell Proliferation; Epitopes, T-Lymphocyte(genetics; immunology); Female; Immunologic Memory; Influenza A virus(genetics; immunology); Lymphocyte Activation; Mice; Orthomyxoviridae Infections(immunology); Sequence Deletion; Spleen(immunology); T-Lymphocyte Subsets(immunology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>79</Volume>
                <Issue>7</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>PB1 703</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSYRRPVGI</LinearSequence>
                        <StartingPosition>703</StartingPosition>
                        <EndingPosition>711</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03431.2</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4330</LocationOfData>
                <EpitopeId>61497</EpitopeId>
                <ReferenceStartingPosition>703</ReferenceStartingPosition>
                <ReferenceEndingPosition>711</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Polymerase basic 1 protein, Also known as RNA-directed RNA polymerase subunit P1.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1 and table 1</LocationOfData>
                        <TCellId>14515</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mutant viruses (NP366-, PA224- or NP366-/PA224-) were used both at the prime and boost innoculations. Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PB1 703</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSYRRPVGI</LinearSequence>
                                        <StartingPosition>703</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03431.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with mutant forms of A/Aichi/2/68 (HK) strain Influenza A virus, lacking functional immunodominant epitopes NP366, PA224 or both, of mice previously inoculated with PR/8/34 (PR) virus strain harboring the same mutation(s), epitope specific CD8+ cells are increased compared to wild type virus inoculated mice. Similar results are seen in bronchoalveolar (BAL) and mediastinal lymph node (MNL) lymphocytes. Similar results are also seen in an intracellular IFN-g PepC assay, particularly at day 7 post challenge. The quality of the response at any time point, measured as the intensity of IFN-g staining is not different in mutant inoculated animals. The primary response to the mutant viruses is not different from the response to wild type virus, so a challenge with a wild type virus does not induce higher epitope specific responses in mutant primed mice than in wild type primed animals.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>14514</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PB1 703</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSYRRPVGI</LinearSequence>
                                        <StartingPosition>703</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03431.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with wild type PR/8/34 (PR) strain, no epitope specific CD8+ cells are seen. The same results are seen in bronchoalveolar (BAL) and mediastinal lymph node (MNL) lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>14516</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mutant viruses (NP366-, PA224- or NP366-/PA224-) were used both at the prime and boost innoculations.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PB1 703</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSYRRPVGI</LinearSequence>
                                        <StartingPosition>703</StartingPosition>
                                        <EndingPosition>711</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03431.2</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with wild type PR/8/34 (PR) strain, no enhancement of the TNF+/IFN-g+ population is seen in mice inoculated with viruses with mutated immunodominant epitopes NP and PA compared to those inoculated with wild type viruses, implying that the quality of the immune response to this epitope is the same in both cases,  even when the number of epitope specific (and IFN-g+) cells is lower in wild type inoculated mice. Similar results are seen in bronchoalveolar fluid lypmhocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>NS2 114</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>RTFSFQLI</LinearSequence>
                        <StartingPosition>114</StartingPosition>
                        <EndingPosition>121</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03508.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4330</LocationOfData>
                <EpitopeId>56055</EpitopeId>
                <ReferenceStartingPosition>114</ReferenceStartingPosition>
                <ReferenceEndingPosition>121</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Non-Structural protein 2.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14543</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2 114</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03508.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with wild type PR/8/34 (PR) strain, no epitope specific IFN-g+ CD8+ cells are seen. Similar results are seen in bronchoalveolar (BAL)  lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14544</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mutant viruses (NP366-, PA224- or NP366-/PA224-) were used both at the prime and boost innoculations. Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2 114</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03508.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with mutant forms of A/Aichi/2/68 (HK) strain Influenza A virus, lacking functional immunodominant epitopes NP366, PA224 or both, of mice previously inoculated with PR/8/34 (PR) virus strain harboring the same mutation(s), epitope specific IFN-g+ CD8+ cells are increased compared to wild type virus inoculated mice. Similar results are seen in bronchoalveolar (BAL) lymphocytes. Nevertheless, the quality of the response at any time point, measured as the intensity of IFN-g staining, is not different in mutant inoculated animals. The primary response to the mutant viruses is not different from the response to wild type virus so a challenge with a WT virus does not induce higher epitope specific responses in mutant (PA- and NP-) primed mice than in WT primed animals, although some compensation is seen in PA-/NP- primed mice.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 5</LocationOfData>
                        <TCellId>14545</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mutant viruses (NP366-, PA224- or NP366-/PA224-) were used both at the prime and boost innoculations.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>NS2 114</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>RTFSFQLI</LinearSequence>
                                        <StartingPosition>114</StartingPosition>
                                        <EndingPosition>121</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03508.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>57</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with WT PR/8/34 (PR) strain, no enhancement of the TNF+/IFN-g+ population is seen in mice inoculated with viruses with mutated immunodominant epitopes NP and PA compared to those inoculated with WT viruses, implying that the quality of the immune response to this epitope is the same in both cases,  even when the number of epitope specific IFN-g+ cells is lower in WT inoculated mice. Similar resuls are seen in bronchoalveolar fluid lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>M1 128</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>MGLIYNRM</LinearSequence>
                        <StartingPosition>128</StartingPosition>
                        <EndingPosition>135</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03485.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4330</LocationOfData>
                <EpitopeId>41602</EpitopeId>
                <ReferenceStartingPosition>128</ReferenceStartingPosition>
                <ReferenceEndingPosition>135</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Matrix protein 1.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>14546</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>122</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>M1 128</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>MGLIYNRM</LinearSequence>
                                        <StartingPosition>128</StartingPosition>
                                        <EndingPosition>135</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03485.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Negative</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with WT PR/8/34 (PR) strain, no epitope specific IFN-g+CD8+ cells are seen. When both inoculations are performed with mutant viruses not expressing immunodominant epitopes NP366 and PA224, no consistent enhancement of the response against this epitope is seen. Similar results are seen in bronchoalveolar (BAL) lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PB1-F2 62</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>LSLRNPILV</LinearSequence>
                        <StartingPosition>62</StartingPosition>
                        <EndingPosition>70</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P0C0U1.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4330</LocationOfData>
                <EpitopeId>39494</EpitopeId>
                <ReferenceStartingPosition>62</ReferenceStartingPosition>
                <ReferenceEndingPosition>70</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>This protein is a novel influenza protein derived for an alternate reading frame ORF in PB1 protein. It was described in Nature Medicine  7, 1306 - 1312 (2001). No Genbank accession number was found for PR/8/34 virus nor for any other virus encoding this epitope sequence.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 9</LocationOfData>
                        <TCellId>14549</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                                <MhcAlleleTypesPresent>
                                    <MhcAlleleId>172</MhcAlleleId>
                                </MhcAlleleTypesPresent>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PB1-F2 62</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>LSLRNPILV</LinearSequence>
                                        <StartingPosition>62</StartingPosition>
                                        <EndingPosition>70</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P0C0U1.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>53</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with wild type A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with WT PR/8/34 (PR) strain, epitope specific IFN-g+ CD8+ cells are low. When both inoculations are performed with mutant viruses not expressing immunodominant epitopes NP366 and PA224, a consistent enhancement of the response against this epitope is seen. Similar results are seen in bronchoalveolar (BAL) lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
            <Epitope>
                <EpitopeName>PA 224</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>SSLENFRAYV</LinearSequence>
                        <StartingPosition>224</StartingPosition>
                        <EndingPosition>233</EndingPosition>
                        <SourceMolecule>
                            <IedbAccession>SRC121</IedbAccession>
                        </SourceMolecule>
                        <SourceOrganismId>211044</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Page 4330</LocationOfData>
                <EpitopeId>61151</EpitopeId>
                <ReferenceStartingPosition>224</ReferenceStartingPosition>
                <ReferenceEndingPosition>233</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Not determined</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Protein name stands for Acid Polymerase.</EpitopeComments>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>14635</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000067</OrganismId>
                                <Sex>F</Sex>
                                <Age>8-10 wk</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Organism</EpitopeRelation>
                                    <Object>
                                        <Organism>
                                            <SubType>Organism</SubType>
                                            <SourceOrganismId>211044</SourceOrganismId>
                                        </Organism>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Not determined</ImmunogenEvidenceCode>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 innoculations, the 1st with source species (10&lt;sup&gt;8&lt;/sup&gt; ID50 i.p); 8 wk. later challenged with 10^7 ID50 HK strain intranasally.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>WT or  mutant viruses (NP366-) were used both at the prime and boost innoculations. Reversing the order or the prime and boost innoculations gave similar results.</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>172</MhcAlleleId>
                            <MhcEvidenceCode>Not determined</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>PA 224</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>SSLENFRAYV</LinearSequence>
                                        <StartingPosition>224</StartingPosition>
                                        <EndingPosition>233</EndingPosition>
                                        <SourceMolecule>
                                            <IedbAccession>SRC121</IedbAccession>
                                        </SourceMolecule>
                                        <SourceOrganismId>211044</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <AssayComments>At 7, 10 &amp; 30 days after challenge with A/Aichi/2/68 (HK) strain Influenza A virus of mice previously inoculated with PR/8/34 (PR) strain, epitope specific CD8+ and also CD8+ IFN-g+ cells are augmented in animals that received mutant viruses lacking the immunodominant epitope NP366, implying the lack of that epitope allows for higher responses against this epitope. Similar results are seen in bronchoalveolar (BAL) and mediastinal lymph node (MNL) lymphocytes.</AssayComments>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

